Harrow (HROW) Income from Continuing Operations (2010 - 2026)
Harrow (HROW) posted quarterly Income from Continuing Operations of 27602000.0 for Q1 2026, down 55.24% year-over-year from 61669208.34 in Q1 2025, and down 365.48% quarter-over-quarter from 10397000.0 in Q4 2025.
Harrow (HROW) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Harrow's Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 27602000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 55.24% year-over-year to 27602000.0; the TTM figure through Mar 2026 stood at 11190000.0 (up 48.42% YoY), while the FY2025 annual figure was 5139000.0, up 70.6% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 27602000.0, down from 10397000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 10397000.0 in Q4 2025, with the low at 27602000.0 in Q1 2026.
- The 5-year median for Income from Continuing Operations is 4391000.0 (2023), against an average of 4996941.18.
- The sharpest annual moves came in 2022 and 2025: Income from Continuing Operations tumbled 1223.5% in 2022, then surged 177.17% in 2025.
- Harrow's Income from Continuing Operations stood at 1055000.0 in 2022, then sank by 967.11% to 9148000.0 in 2023, then jumped by 174.08% to 6777000.0 in 2024, then jumped by 53.42% to 10397000.0 in 2025, then sank by 365.48% to 27602000.0 in 2026.
- Business Quant data shows HROW's Income from Continuing Operations at 27602000.0 in Q1 2026, 10397000.0 in Q4 2025, and 1020000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Harrow | 1.55 Bn | 1.47 Bn | 50.36 Mn | -17.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -17.27 Mn |
| Mar 31, 2026 | -27.60 Mn |
| Dec 31, 2025 | 10.40 Mn |
| Sep 30, 2025 | 1.02 Mn |
| Jun 30, 2025 | 5.00 Mn |
| Mar 31, 2025 | -17.78 Mn |
| Dec 31, 2024 | 6.78 Mn |
| Sep 30, 2024 | -4.22 Mn |
| Jun 30, 2024 | -6.47 Mn |
| Mar 31, 2024 | -13.57 Mn |
| Dec 31, 2023 | -9.15 Mn |
| Sep 30, 2023 | -4.39 Mn |
| Jun 30, 2023 | -4.23 Mn |
| Mar 31, 2023 | -6.64 Mn |
| Dec 31, 2022 | 1.06 Mn |
| Sep 30, 2022 | -6.46 Mn |
| Jun 30, 2022 | -6.24 Mn |
| Mar 31, 2022 | -2.44 Mn |
| Dec 31, 2021 | -7.29 Mn |
| Sep 30, 2021 | -8.33 Mn |